Provided herein are, inter alia, compositions including recombinant oncolytic herpes simplex viruses that express SARS-CoV spike (S) protein and viral vectors including nucleic acid sequences encoding SARS-CoV S protein. The compositions are useful for eliciting antibodies to SARS-CoV. The compositions are contemplated to be particularly useful for methods of treating and preventing SARS coronavirus infections in cancer patients.

The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a laminin polypeptide (e.g., a human laminin polypeptide) and/or a filaggrin polypeptide (e g , a human filaggrin polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of Junctional Epidermolysis Bullosa); and articles of manufacture or kits thereof.

The present invention relates to the field of (vector) vaccines, and especially to novel EHV's having an inactivation of UL18 and/or UL8. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

Provided herein are methods for generating reversion free attenuated and/or replication incompetent vaccine vectors and their use in vaccine compositions and vaccination. In particular, the use of a codon shuffled helper gene is used to produce compositions comprising replication incompetent virus.

The present invention relates to the field of (vector) vaccines, and especially to novel EHV's having an inactivation of UL18 and/or UL8. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

The disclosure provides methods for generating reversion free attenuated and/or replication incompetent vaccine vectors and their use in vaccine compositions and vaccination.

The present invention relates to a recombinant Koi herpesvirus (KHV), methods for the production of such KHV, cells comprising such KHV and the use of such KHV as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by Koi herpesvirus in carp such as Cyprinus carpio carpio or Cyprinus carpio koi.

The present invention relates to a recombinant Koi herpesvirus (KHV), methods for the production of such KHV, cells comprising such KHV and the use of such KHV as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by Koi herpesvirus in carp such as Cyprinus carpio carpio or Cyprinus carpio koi.

The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.

This application describes a modified herpes simplex virus type 1 (HSV-1), capable of being efficiently produced in suspension cell culture, and a method of producing HSV-1 vectors in suspension cell culture.